TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
TransCode (NASDAQ: RNAZ) announced an exclusive, worldwide, fully paid-up royalty-free license from Unleash to develop three adenovirus-based oncolytic candidates—UIO-524, UIO-525 and UIO-526—via an all-stock transaction dated March 3, 2026.
Unleash will receive 1,136,364 shares of a new non-voting convertible preferred stock, representing 6.8% fully diluted upon conversion; the lead candidate UIO-524 targets muscle-invasive bladder cancer (MIBC).
TransCode Therapeutics (NASDAQ: RNAZ) announced publication of a peer-reviewed preclinical manuscript, Template-Directed RIG-I Agonist Assembly, published February 19, 2026 in Molecular Imaging and Biology.
The study reports a tumor-selective RIG-I agonist approach that uses overexpressed oncogenic microRNAs (eg, miRNA-21) as intracellular assembly templates and highlights image-guided delivery using TransCode's TTX nanoparticle platform, which is currently in clinical trials.
TransCode (NASDAQ: RNAZ) and Quantum Leap submitted an IND amendment to the FDA for a planned Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer (NCT05868226).
The PRE-I-SPY platform trial will enroll up to 45 ctDNA-positive patients post‑curative therapy, aims to start in H1 2026, and will be led by Dr. Paula Pohlmann.
TransCode Therapeutics (NASDAQ: RNAZ) reported preclinical data showing its lead candidate TTX-MC138 reaches orthotopic glioblastoma tumors after intravenous dosing and produces sustained target engagement against miR-10b.
The study in murine models reported a 5-fold increase in apoptotic activity in tumors and a statistically significant survival benefit. IND‑enabling studies, PK/biodistribution, and toxicity work have been completed, and Phase 1 safety data exist in non-CNS patients; a Phase 2a trial is anticipated in H1 2026.
TransCode Therapeutics (NASDAQ: RNAZ) announced the appointment of Jack E. Stover to its Board of Directors effective Dec. 22, 2025.
Mr. Stover will join the Audit and Nominating Committees while Dr. Magda Marquet steps down from the Audit Committee. He brings over three decades of executive experience across drug development, diagnostics, specialty pharmaceuticals, and capital formation and has led mergers, financings, and company sales.
Notable roles cited include chairman of Traws Pharma, director and audit chair at Onconova, CEO of NorthView Acquisition Corp from March 2021 to July 2025, director of Profusa, and prior CEO roles at Interpace Biosciences and Antares Pharma (sale of Antares to Halozyme for in excess of $900 million).
TransCode Therapeutics (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative announced a collaboration to evaluate TTX-MC138 in the Quantum Leap PRE-I-SPY Phase 2a dose-expansion trial for colorectal cancer.
The Phase 2a will enroll up to 45 patients with ctDNA-positive minimal residual disease who completed curative-intent therapy, is planned to begin in H1 2026, and will be led by Dr. Paula Pohlmann at MD Anderson. The move follows TransCode's Phase 1a observation of an encouraging safety profile and durable anti-tumor effects, which the companies say support further efficacy testing in the MRD setting where recurrence risk is high.
TransCode Therapeutics (NASDAQ: RNAZ) on November 17, 2025 appointed Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer, initially part-time. Dr. Janicot brings >35 years in pharmaceutical research and early clinical development with expertise in RNA biology, translational medicine, and oncology strategy. He will support strategic R&D and clinical development for lead programs TTX-MC138 and Seviprotimut-L as they advance toward late-stage trials.
Dr. Janicot founded JMi ONConsulting, has led programs at Janssen, and authored >360 scientific works.
TransCode Therapeutics (NASDAQ: RNAZ) reported completion of its Phase 1a trial of TTX-MC138, an investigational miR-10b inhibitor, and met the trial's primary safety endpoint. Sixteen patients were treated across four dose levels with no dose-limiting toxicities observed and a recommended Phase 2 dose established. Median treatment duration was 4 months (range 2–12 months); three patients remain on study. Forty-four percent (7/16) had stable disease ≥4 months. Positive pharmacodynamic effects were seen across the dose range. Data are preliminary; a poster presentation is scheduled for ESMO, Oct 17–21, 2025, and a Phase 2a trial is planned.
TransCode Therapeutics (NASDAQ: RNAZ) announced on October 8, 2025 the acquisition of 100% of Polynoma and a concurrent $25 million equity investment from CK Life Sciences. The deal adds Polynoma’s Phase 3–ready seviprotimut-L (a polyvalent shed‑antigen vaccine for adjuvant treatment of stage IIB/IIC melanoma) to TransCode’s microRNA pipeline.
Proceeds will primarily advance TransCode’s lead microRNA asset, TTX‑MC138, into a Phase 2 trial. Philippe Calais becomes CEO and remains board chair; Tom Fitzgerald returns to CFO; Elizabeth Czerepak joins as independent board member and audit chair. The company expects to retain Polynoma development, finance, and manufacturing staff.